Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 25,000 shares at $47.64 ($1.2M) on 2025-10-01, disclosed to the SEC on 2025-10-03.
Scheduled sale ($1.2M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.64 | 8,299 | $395K | 33.1% |
| 2 | $47.64 | 8,299 | $395K | 33.1% |
| 3 | $47.98 | 4,201 | $202K | 16.9% |
| 4 | $47.98 | 4,201 | $202K | 16.9% |
| Total | $47.75 avg | 25,000 | $1.2M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $269K | — | Filing → |